^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BA1104 (nivolumab biosimilar)

    i
    Other names: BA1104, LY01015, LY-01015, BA 1104, BA-1104, LY 01015
    Associations

    News

    Trials
    Company:
    Luye Group
    Drug class:
    PD1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    9ms
    A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P3, N=510, Recruiting, Shandong Boan Biotechnology Co., Ltd | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • cisplatin • 5-fluorouracil • BA1104 (nivolumab biosimilar)
    over1year
    A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P3, N=510, Not yet recruiting, Shandong Boan Biotechnology Co., Ltd
    New P3 trial • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • cisplatin • 5-fluorouracil • BA1104 (nivolumab biosimilar)